Zdrowie i gospodarka · 21/11/1996
FDA Clears Way for Approval of Testosterone Propionate 2% Ointment
The Food and Drug Administration (FDA) has determined that testosterone propionate 2% ointment (Perandren Ointment) was not withdrawn from sale for reasons of safety or effectiveness, allowing the FDA to approve abbreviated new drug applications (ANDA's) for the product.
Source: Federal Register — Food and Drug AdministrationOpen original release →